Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 11/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22394874 | 0.88 | GRM5 (0.37) | — | |
| SCHEMBL30714422 | 0.88 | GRM5 (0.37) | — | |
| SCHEMBL22394863 | 0.79 | ATF4 (0.48) | — | |
| SCHEMBL30714436 | 0.79 | ATF4 (0.48) | — | |
| SCHEMBL22395381 | 0.79 | ATF4 (0.48) | — | |
| SCHEMBL30714426 | 0.79 | ATF4 (0.48) | — | |
| SCHEMBL23610394 | 0.77 | S1PR1 (0.35) | RARARARBRARGNR1H4HDAC4 | |
| SCHEMBL22394958 | 0.76 | RARA (0.36) | TRPV1RARARARBRARGBDKRB1 | |
| SCHEMBL30714419 | 0.76 | RARA (0.36) | TRPV1RARARARBRARGBDKRB1 | |
| SCHEMBL19555951 | 0.74 | ATF4 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704096-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20210205277-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-07-08 | — | — | US | disclosed |
| US-20210205277-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205277-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | TRPV1 2490/4885KCNH2 4816/4885RARA 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.